These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

884 related articles for article (PubMed ID: 28831036)

  • 1. BRCA locus-specific loss of heterozygosity in germline BRCA1 and BRCA2 carriers.
    Maxwell KN; Wubbenhorst B; Wenz BM; De Sloover D; Pluta J; Emery L; Barrett A; Kraya AA; Anastopoulos IN; Yu S; Jiang Y; Chen H; Zhang NR; Hackman N; D'Andrea K; Daber R; Morrissette JJD; Mitra N; Feldman M; Domchek SM; Nathanson KL
    Nat Commun; 2017 Aug; 8(1):319. PubMed ID: 28831036
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Methylation not a frequent "second hit" in tumors with germline BRCA mutations.
    Dworkin AM; Spearman AD; Tseng SY; Sweet K; Toland AE
    Fam Cancer; 2009; 8(4):339-46. PubMed ID: 19340607
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Diverse
    Weigelt B; Comino-Méndez I; de Bruijn I; Tian L; Meisel JL; García-Murillas I; Fribbens C; Cutts R; Martelotto LG; Ng CKY; Lim RS; Selenica P; Piscuoglio S; Aghajanian C; Norton L; Murali R; Hyman DM; Borsu L; Arcila ME; Konner J; Reis-Filho JS; Greenberg RA; Robson ME; Turner NC
    Clin Cancer Res; 2017 Nov; 23(21):6708-6720. PubMed ID: 28765325
    [No Abstract]   [Full Text] [Related]  

  • 4. High prevalence of deleterious BRCA1 and BRCA2 germline mutations in arab breast and ovarian cancer patients.
    Alhuqail AJ; Alzahrani A; Almubarak H; Al-Qadheeb S; Alghofaili L; Almoghrabi N; Alhussaini H; Park BH; Colak D; Karakas B
    Breast Cancer Res Treat; 2018 Apr; 168(3):695-702. PubMed ID: 29297111
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Loss of heterozygosity at BRCA1 locus is significantly associated with aggressiveness and poor prognosis in breast cancer.
    Okada S; Tokunaga E; Kitao H; Akiyoshi S; Yamashita N; Saeki H; Oki E; Morita M; Kakeji Y; Maehara Y
    Ann Surg Oncol; 2012 May; 19(5):1499-507. PubMed ID: 22179631
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of Oophorectomy on Survival After Breast Cancer in BRCA1 and BRCA2 Mutation Carriers.
    Metcalfe K; Lynch HT; Foulkes WD; Tung N; Kim-Sing C; Olopade OI; Eisen A; Rosen B; Snyder C; Gershman S; Sun P; Narod SA
    JAMA Oncol; 2015 Jun; 1(3):306-13. PubMed ID: 26181175
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A systematic review on the frequency of BRCA promoter methylation in breast and ovarian carcinomas of BRCA germline mutation carriers: Mutually exclusive, or not?
    Vos S; van Diest PJ; Moelans CB
    Crit Rev Oncol Hematol; 2018 Jul; 127():29-41. PubMed ID: 29891109
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Methylation and protein expression of DNA repair genes: association with chemotherapy exposure and survival in sporadic ovarian and peritoneal carcinomas.
    Swisher EM; Gonzalez RM; Taniguchi T; Garcia RL; Walsh T; Goff BA; Welcsh P
    Mol Cancer; 2009 Jul; 8():48. PubMed ID: 19602291
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparable frequency of BRCA1, BRCA2 and TP53 germline mutations in a multi-ethnic Asian cohort suggests TP53 screening should be offered together with BRCA1/2 screening to early-onset breast cancer patients.
    Lee DS; Yoon SY; Looi LM; Kang P; Kang IN; Sivanandan K; Ariffin H; Thong MK; Chin KF; Mohd Taib NA; Yip CH; Teo SH
    Breast Cancer Res; 2012 Apr; 14(2):R66. PubMed ID: 22507745
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Germ-line mutations in BRCA1 or BRCA2 in the normal breast are associated with altered expression of estrogen-responsive proteins and the predominance of progesterone receptor A.
    Mote PA; Leary JA; Avery KA; Sandelin K; Chenevix-Trench G; Kirk JA; Clarke CL;
    Genes Chromosomes Cancer; 2004 Mar; 39(3):236-48. PubMed ID: 14732925
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of germline and somatic events in candidate BRCA-like genes on breast-tumor signatures.
    Bodily WR; Shirts BH; Walsh T; Gulsuner S; King MC; Parker A; Roosan M; Piccolo SR
    PLoS One; 2020; 15(9):e0239197. PubMed ID: 32997669
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Accurate detection and quantification of epigenetic and genetic second hits in BRCA1 and BRCA2-associated hereditary breast and ovarian cancer reveals multiple co-acting second hits.
    Van Heetvelde M; Van Bockstal M; Poppe B; Lambein K; Rosseel T; Atanesyan L; Deforce D; Van Den Berghe I; De Leeneer K; Van Dorpe J; Vral A; Claes KBM
    Cancer Lett; 2018 Jul; 425():125-133. PubMed ID: 29580810
    [TBL] [Abstract][Full Text] [Related]  

  • 13. BRCA1/2 mutations and expression: response to platinum chemotherapy in patients with advanced stage epithelial ovarian cancer.
    Dann RB; DeLoia JA; Timms KM; Zorn KK; Potter J; Flake DD; Lanchbury JS; Krivak TC
    Gynecol Oncol; 2012 Jun; 125(3):677-82. PubMed ID: 22406760
    [TBL] [Abstract][Full Text] [Related]  

  • 14. BRCA1 and BRCA2 mutations and clinical interpretation in 398 ovarian cancer patients: comparison with breast cancer variants in a similar population.
    Cardoso FC; Goncalves S; Mele PG; Liria NC; Sganga L; Diaz Perez I; Podesta EJ; Solano AR
    Hum Genomics; 2018 Aug; 12(1):39. PubMed ID: 30103829
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prediction of BRCA2-association in hereditary breast carcinomas using array-CGH.
    Joosse SA; Brandwijk KI; Devilee P; Wesseling J; Hogervorst FB; Verhoef S; Nederlof PM
    Breast Cancer Res Treat; 2012 Apr; 132(2):379-89. PubMed ID: 20614180
    [TBL] [Abstract][Full Text] [Related]  

  • 16.
    Lips EH; Debipersad RD; Scheerman CE; Mulder L; Sonke GS; van der Kolk LE; Wesseling J; Hogervorst FB; Nederlof PM
    Clin Cancer Res; 2017 Mar; 23(5):1236-1241. PubMed ID: 27620280
    [No Abstract]   [Full Text] [Related]  

  • 17. A Dominantly Inherited 5' UTR Variant Causing Methylation-Associated Silencing of BRCA1 as a Cause of Breast and Ovarian Cancer.
    Evans DGR; van Veen EM; Byers HJ; Wallace AJ; Ellingford JM; Beaman G; Santoyo-Lopez J; Aitman TJ; Eccles DM; Lalloo FI; Smith MJ; Newman WG
    Am J Hum Genet; 2018 Aug; 103(2):213-220. PubMed ID: 30075112
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Germline BRCA1 mutations and loss of the wild-type allele in tumors from families with early onset breast and ovarian cancer.
    Merajver SD; Frank TS; Xu J; Pham TM; Calzone KA; Bennett-Baker P; Chamberlain J; Boyd J; Garber JE; Collins FS
    Clin Cancer Res; 1995 May; 1(5):539-44. PubMed ID: 9816013
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Biallelic
    Wineland D; Le AN; Hausler R; Kelly G; Barrett E; Desai H; Wubbenhorst B; Pluta J; Bastian P; Symecko H; D'Andrea K; Doucette A; Gabriel P; Reiss KA; Nayak A; Feldman M; Domchek SM; Nathanson KL; Maxwell KN; ;
    JCO Precis Oncol; 2023 Aug; 7():e2300036. PubMed ID: 37535879
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Germline mutations of BRCA1 and BRCA2 in Korean breast and/or ovarian cancer families.
    Kang HC; Kim IJ; Park JH; Kwon HJ; Won YJ; Heo SC; Lee SY; Kim KH; Shin Y; Noh DY; Yang DH; Choe KJ; Lee BH; King SB; Park JG
    Hum Mutat; 2002 Sep; 20(3):235. PubMed ID: 12204006
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 45.